Surmodics, Inc. announced the publication of results from the TRANSCEND clinical trial. The global randomized study demonstrat ...

Division of Cardiology, Duke University Health System, Durham, NC (M.T., W.S.J., R.V.S., J.R., J.A.G.). Duke Clinical Research Institute, Durham, NC (M.T., W.S.J., J ...

Surmodics, Inc. , a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced the publication of the TRANSCEND clinical trial, a global ...

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced the publication of the TRANSCEND clinical trial, ...

"Compared to balloon angioplasty or self-expanding nitinol stents that are commonly used to treat patients with narrowing in their femoropopliteal artery, balloon expandable scaffolds with high ...

A total of 446 patients with femoropopliteal artery disease (Rutherford stages 2–4) were randomized to either the SurVeil DCB (n = 222) or the IN.PACT Admiral DCB (n = 224). Patients were ...